新型主动脉瓣生物瓣膜早期与中期结局的系统评价
该系统评价纳入15项研究共3202例患者,评估Inspiris RESILIA生物瓣膜行主动脉瓣置换的早期与中期结局,平均随访至5.3年。院内或30天死亡率0-2.8%,中期全因死亡免除率最高85.4%,中期随访中微量/轻度瓣周漏0-3.0%,重度瓣周漏最高2.0%。亚组荟萃分析显示Inspiris RESILIA与PERIMOUNT Magna Ease在死亡率和卒中方面无统计学显著差异。
要点
- 纳入15项研究共3202例患者,平均随访至5.3年,评估Inspiris RESILIA生物瓣膜早期与中期结局。
- 院内或30天死亡率0-2.8%,中期全因死亡免除率最高85.4%。
- 中期随访微量/轻度瓣周漏0-3.0%,重度瓣周漏最高2.0%。
核心结论
- 新型主动脉生物瓣膜的中期安全性和血流动力学性能数据令人鼓舞。
- 仍需与其他生物瓣膜进行进一步比较研究并延长随访,以证实该新型瓣膜的耐久性和安全性。
研究设计与样本
- 系统评价,检索所有评估Inspiris RESILIA生物瓣膜行主动脉瓣置换后早期与中期结局的研究,纳入至少20例患者,发表时间不限。
- 共识别416项研究,其中15项符合纳入标准,合计3202例患者,平均随访至5.3年。
主要发现
- 各研究患者平均年龄52.2-75.1岁,单纯主动脉瓣置换占39.0-86.4%。
- 院内或30天术后死亡率为0-2.8%,中期随访全因死亡免除率最高85.4%。
- 中期随访研究中,微量/轻度瓣周漏检出率0-3.0%,重度瓣周漏最高2.0%。
- 亚组荟萃分析显示Inspiris RESILIA与PERIMOUNT Magna Ease生物瓣膜在死亡率(P=0.98,比值比1.02,95%置信区间0.36-2.83)和卒中(P=0.98,比值比1.01,95%置信区间0.38-2.73)方面无统计学显著差异。
关键数值与推荐
- 纳入标准:评估Inspiris RESILIA生物瓣膜行主动脉瓣置换后早期与中期结局,至少20例患者,发表时间不限。
- 院内或30天术后死亡率0-2.8%。
- 中期随访全因死亡免除率最高85.4%。
- 中期随访微量/轻度瓣周漏0-3.0%,重度瓣周漏最高2.0%。
- Inspiris RESILIA与PERIMOUNT Magna Ease比较:死亡率P=0.98,比值比1.02,95%置信区间0.36-2.83;卒中P=0.98,比值比1.01,95%置信区间0.38-2.73。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出仍需与其他生物瓣膜进行进一步比较研究并延长随访,以证实该新型瓣膜的耐久性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: While current data show a clear trend towards the use of bioprosthetic valves during aortic valve replacement (AVR), durability of bioprosthetic valves remains the most important concern. We conducted a 1st systematic review of all available evidence that analysed early and mid-term outcomes after AVR using the Inspiris RESILIA™ bioprosthesis. METHODS: A systematic literature search was performed to identify all relevant studies evaluating early and mid-term outcomes after AVR using the Inspiris RESILIA bioprosthesis and including at least 20 patients with no restriction on the publication date. Subgroup meta-analysis was performed to compare Inspiris RESILIA and PERIMOUNT Magna Ease bioprosthesis and to pool the early postoperative mortality and stroke rates. RESULTS: A total of 416 studies were identified, of which 15 studies met the eligibility criteria. The studies included a total of 3202 patients with an average follow-up of up to 5.3 years. The average age of patients across the studies was 52.2-75.1 years. Isolated AVR was performed in 39.0-86.4% of patients. In-hospital or 30-day postoperative mortality was 0-2.8%. At the mid-term follow-up, freedom from all-cause mortality was up to 85.4%. Among studies with mid-term follow-up, trace/mild paravalvular leak was detected in 0-3.0%, while major paravalvular leak was found only in up to 2.0% of patients. No statistically significant differences in terms of mortality (P = 0.98, odds ratio 1.02, 95% confidence interval 0.36-2.83) and stroke (P = 0.98, odds ratio 1.01, 95% confidence interval 0.38-2.73) between the Inspiris RESILIA bioprosthesis and PERIMOUNT Magna Ease bioprosthesis were observed in the subgroup meta-analysis. CONCLUSIONS: Mid-term data on the safety and haemodynamic performance of the novel aortic bioprosthesis are encouraging. Further comparative studies with other bioprostheses and longer follow-up are still required to endorse durability and safety of the novel bioprosthesis.
引用
- Sef D, Thet MS, Klokocovnik T, et al. Early and mid-term outcomes after aortic valve replacement using a novel tissue bioprosthesis: a systematic review. Eur J Cardiothorac Surg. 2024. PMID: 38331412. doi:10.1093/ejcts/ezae045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。